Genzyme, Industry Analysts Relieved By Particulars In Draft Consent Decree
This article was originally published in The Pink Sheet Daily
Executive Summary
Unveiling its first-quarter financial results, Genzyme reports significant year-over-year sales decreases for Cerezyme and Fabrazyme.
You may also be interested in...
Genzyme Warns Of Further Shortages Of Cerezyme, Fabrazyme
Fabrazyme may be unavailable in some regions from July through September, the company warned.
Genzyme Warns Of Further Shortages Of Cerezyme, Fabrazyme
Fabrazyme may be unavailable in some regions from July through September, the company warned.
With Proxy Fight Averted, Genzyme Can Review Damage Done By A Year Of Manufacturing Troubles
Now that Genzyme has avoided a proxy fight with Carl Icahn and associates, the biotech's next step likely will be to consider the damage left by a year's worth of manufacturing woes and the problems that resulted, including shortages of its top-selling products, the launch of new competition to those drugs, and an FDA consent decree governing operations at its Allston Landing, Mass., plant